natgillin/translations-raw huggingface dataset:
A decision must be made whether to discontinue breastfeeding or to discontinue Aerivio Spiromax therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman. 
Odločiti se je treba med prenehanjem dojenja in prenehanjem/prekinitvijo zdravljenja z zdravilom Aerivio Spiromax, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
The data presented below refer to a lower dose of the fixed-dose combination containing these two actives, a dose and strength which is not available for Aerivio Spiromax. 
Podatki, predstavljeni v nadaljevanju, se nanašajo na manjši odmerek fiksne kombinacije odmerka, ki vsebuje ti dve zdravilni učinkovini; odmerek in jakost, v kateri zdravilo Aerivio Spiromax ni na voljo.
If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical 
Če se pri bolniku pojavijo simptomi, kot so zamegljen vid ali druge motnje vida, ga je potrebno upoštevati za napotitev k oftalmologu zaradi ovrednotenja možnih vzrokov, ki lahko vključujejo katarakto, glavkom ali redke bolezni, kot je centralna serozna horioretinopatija, o katerih so poročali po sistemski in topični uporabi
• Feeling shaky (tremor) and fast or uneven heart beat (palpitations) - these are usually harmless and get 
• občutek drhtenja (tremor) in hiter ali nereden srčni utrip (palpitacije) - ti neželeni učinki so običajno neškodljivi in se med nadaljevanjem zdravljenja zmanjšajo;
• A reduction in the amount of potassium in the blood (you may get an uneven heartbeat, muscle 
• znižanje ravni kalija v krvi (srčni utrip lahko postane neenakomeren, mišična oslabelost, krči).
There is also an increased risk of systemic undesirable effects when combining fluticasone propionate with other potent CYP3A inhibitors (see section 4.5). 
Tveganje za sistemske neželene učinke je večje tudi med uporabo kombinacije flutikazonpropionata in drugih močnih zaviralcev CYP3A (glejte poglavje 4.5).
There is no conclusive clinical evidence for intra-class differences in the magnitude of the pneumonia risk 
Ni dokončnih kliničnih dokazov, da se stopnja tveganja za pljučnico znotraj skupine inhalacijskih
When stabilised, treatment should be continued with an inhaled corticosteroid at the recommended dose. 
Po stabilizaciji je treba zdravljenje nadaljevati s priporočenim odmerkom inhalacijskega kortikosteroida.
• Do not use this medicine after the expiry date which is stated on the carton and the label of your inhaler after EXP. 
• Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in nalepki inhalatorja, poleg oznake EXP. Rok uporabnosti zdravila se izteče na zadnji dan navedenega meseca.
Risk factors for pneumonia in patients with COPD include current smoking, older age, low body mass index 
Med dejavniki tveganja za pljučnico pri bolnikih s KOPB so trenutno kajenje, višja starost, nizek indeks telesne mase (ITM) in huda KOPB.
• Depression or aggression (although these effects are more likely to occur in children when prescribed this combination of drugs but in a lower strength). 
• depresija ali agresija (čeprav je bolj verjetno, da se bodo ti učinki pojavili pri otrocih, ki se jim predpiše ta kombinacija zdravil v manjši jakosti);
EXP Use within 3 months of removing from foil wrapping. 
EXP Uporabite v 3 mesecih od odstranitve ovoja iz folije.
If you forget to use Aerivio Spiromax Do not take a double dose to make up for a forgotten dose. 
Če ste pozabili vzeti zdravilo Aerivio Spiromax Ne vzemite dvojnega odmerka, če ste pozabili vzeti prejšnji odmerek.
Paradoxical bronchospasm responds to a rapid-acting bronchodilator and should be treated straightaway. 
Paradoksni bronhospazem se odziva na hitrodelujoči bronhodilatator in ga je treba zdraviti takoj.
Keep the mouthpiece closed all the time unless you are about to use your inhaler. 
Ustnik naj bo vedno zaprt, razen če nameravate inhalator uporabiti.
• Bruising and fractures. 
• modrice in zlomi;
• Behavioural changes, such as being unusually active and irritable (although these effects occur mainly in children when prescribed this combination of drugs but in a lower strength). 
• vedenjske spremembe, kot je neobičajna aktivnost in razdražljivost (čeprav se ti učinki običajno pojavijo pri otrocih, ki se jim predpiše ta kombinacija zdravil v manjši jakosti);
Cardiac arrhythmias (including supraventricular tachycardia and extrasystoles). 
Pogostnost motnje srčnega ritma (vključno s supraventrikularno tahikardijo in ekstrasistolami)
All patients 
Posebne skupine bolnikov
Patients who have required high dose emergency corticosteroid therapy in the past may also be at risk. 
Ogroženi so lahko tudi bolniki, ki so v preteklosti potrebovali velike odmerke nujnega zdravljenja s kortikosteroidi.
Prior to run-in, subjects discontinued use of previous COPD medications except short-acting bronchodilators. 
Pred uvajanjem so osebe prenehale uporabljati prejšnja zdravila proti KOPB, razen kratkodelujočih bronhodilatatorjev.
It should not be used for the treatment of patients with mild or moderate asthma or for the initiation of treatment for patients with severe asthma unless the requirement for such a high dose of the corticosteroid together with a long-acting β2 agonist has been established previously. 
Ne sme se ga uporabljati za zdravljenje bolnikov z blago ali zmerno astmo ali za uvedbo zdravljenja pri bolnikih s hudo astmo, razen če je bilo predhodno ugotovljeno, da je tako velik odmerek kortikosteroida skupaj z
Patients should be asked to continue treatment but to seek medical advice if asthma symptoms remain uncontrolled or worsen after initiation on Aerivio Spiromax. 
Bolnikom je treba naročiti, naj z zdravljenjem nadaljujejo, vendar naj se posvetujejo z zdravnikom, če simptomi astme niso pod nadzorom ali če se po uvedbi zdravila Aerivio Spiromax poslabšajo.
For patients with COPD cessation of therapy may also be associated with symptomatic decompensation and should be supervised by 
Tudi pri bolnikih s KOPB je opustitev zdravljenja lahko povezana s simptomatsko dekompenzacijo in mora zato potekati pod zdravniškim nadzorom.
A double blind, randomised, parallel group study in 318 patients with persistent asthma aged ≥18 years evaluated the safety and tolerability of administering two inhalations twice daily (double dose) of salmeterol/fluticasone propionate for two weeks. 
V dvojno slepi, randomizirani študiji z vzporednimi skupinami pri 318 bolnikih s perzistentno astmo, starih ≥ 18 let, so ocenili varnost in prenašanje pri dvotedenskem dajanju dveh inhalacij (dvojni odmerek) salmeterola/flutikazonpropionata dvakrat na dan.
The mean PIFR achieved by patients with asthma or COPD with optimal training (i.e. forceful inhalation) was over 60 L/min, a flow rate at which both devices studied are known to deliver comparable amounts of drug to the lungs. 
Povprečni PIFR, ki so ga z optimalnim usposabljanjem (tj. silovit vdih) dosegli bolniki z astmo ali KOPB, je bil več kot 60 l/min, kar je hitrost pretoka, s katero oba preučena pripomočka dostavita primerljivo količino zdravila v pljuča.
The trials had a 4 week run-in period during which all subjects received open-label salmeterol/FP 50/250 to standardize COPD pharmacotherapy and stabilise disease prior to randomisation to blinded study medication for 52 weeks. 
Preskušanji sta imeli 4-tedensko uvajalno obdobje, v katerem so vse osebe odprto prejemale salmeterol/FP 50/250 mikrogramov za standardiziranje farmakoterapije KOPB in stabiliziranje bolezni pred randomizacijo v 52-tedensko slepo obdobje prejemanja zdravila v okviru študije.
- if you are allergic (hypersensitive) to salmeterol, fluticasone propionate or any of the other ingredients of this medicine (listed in section 6). 
Ne uporabljajte zdravila Aerivio Spiromax: - če ste alergični (preobčutljivi) na salmeterol, flutikazonpropionat ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Paradoxical bronchospasm may occur with an immediate increase in wheezing and shortness of breath after dosing. 
Pojavi se lahko paradoksni bronhospazem, ki se kaže kot takojšnje povečanje piskajočega dihanja in zasoplosti po uporabi odmerka.
Patients with severe asthma and COPD were shown to be able to generate sufficient inspiratory flow rate when they breathed in forcefully through the Spiromax device to enable the delivery of the required therapeutic dose to the lungs (see also section 5.1 - last five paragraphs) 
Bolniki s hudo astmo in KOPB so s silovitim vdihom skozi pripomoček Spiromax dosegli ustrezno hitrost vdišnega toka, kar je omogočilo dostavo potrebnega terapevtskega odmerka v pljuča (glejte tudi poglavje 5.1, zadnjih pet
The main pathway is metabolism to an inactive carboxylic acid metabolite, by the cytochrome P450 enzyme CYP3A4. 
Glavna pot je presnova v neaktivni presnovek karboksilne kisline s pomočjo encima CYP3A4 citokroma P450.
Not for use in children or adolescents under 18 years of age. 
Ni za uporabo pri otrocih in mladostnikih, mlajših od 18 let.
Before using your Aerivio Spiromax for the first time, you need to prepare it for use as follows: 
Pred prvo uporabo zdravila Aerivio Spiromax ga morate na uporabo pripraviti na naslednji način:
In a study in 158 children aged 6 to 16 years with symptomatic asthma, the combination of salmeterol/ fluticasone propionate is as efficacious as doubling the dose of fluticasone propionate in respect of symptom control and lung function. 
V študiji na 158 otrocih, starih od 6 do 16 let, s simptomatsko astmo, je v smislu nadzora simptomov in pljučne funkcije kombinacija salmeterola/flutikazonpropionata enako učinkovita kot podvojitev odmerka flutikazonpropionata.
Use your fast acting ‘reliever' inhaler to help your breathing and tell your doctor straight away. 
Uporabite hitrodelujoče "olajševalno" zdravilo, ki vam pomaga dihati, in o tem takoj obvestite
The data from the study indicated that regardless of age and underlying disease severity, children, adolescents and adults with asthma as well as patients with COPD were able to achieve inspiratory flow rates through the Spiromax device that were similar to those generated through the marketed multi-dose dry powder inhaler device. 
Podatki iz študije kažejo, da so lahko otroci, mladostniki in odrasli z astmo ter bolniki s KOPB, ne glede na starost in resnost osnovne bolezni, skozi pripomoček Spiromax dosegli inspiratorne hitrosti pretoka podobne tistim z večodmernimi inhalacijskimi pripomočki za suhi prašek, ki so na trgu.
If you accidentally take more doses than is recommended, talk to your doctor or pharmacist. 
Če po nezgodi uporabite več odmerkov, kot je priporočeno, se posvetujte z zdravnikom ali farmacevtom.
The use of Aerivio Spiromax follows three simple steps: open, breathe and close which are outlined below. 
Zdravilo Aerivio Spiromax se uporablja v treh preprostih korakih: odprite, vdihnite in zaprite, kot je
The studies described were carried out with a previously authorised product available in three different strengths; the studies were not carried out with 
Opisane študije so bile izvedene s predhodno odobrenim zdravilom, ki je bilo na voljo v treh različnih jakostih; študije niso bile izvedene z zdravilom Aerivio Spiromax.
Each Aerivio Spiromax inhaler contains 60 inhalations and has a white body with a semi-transparent yellow 
En inhalator zdravila Aerivio Spiromax vsebuje 60 inhalacij in ima belo telo s polprozornim rumenim
There were no differences in safety parameters between the two treatment arms. 
Med obema zdravljenima skupinama glede varnostnih parametrov ni bilo razlik.
There were no differences between the two treatment arms. 
Med obema zdravljenima skupinama ni bilo razlik.
- The other ingredient is lactose monohydrate (see section 2 under ‘Aerivio Spiromax contains lactose'). 
- Druga sestavina zdravila je laktoza monohidrat (glejte poglavje 2 "Zdravilo Aerivio Spiromax
Aerivio Spiromax is not indicated for use in children and adolescents under the age of 18 years (see Section 4.2). 
Zdravilo Aerivio Spiromax ni namenjeno za uporabo pri otrocih in mladostnikih, mlajših od 18 let (glejte poglavje 4.2).
• Beta blockers (such as atenolol, propranolol and sotalol). 
• Antagonisti adrenergičnih receptorjev beta (na primer atenolol, propranolol, sotalol).
Possible systemic effects in these age groups include Cushing's syndrome, Cushingoid features, adrenal suppression and growth retardation in children and adolescents (see section 4.4). 
Možni neželeni učinki v tej starostni skupini vključujejo Cushingov sindrom, cushingoididne značilnosti, zavrtje nadledvičnih žlez in upočasnitev rasti pri otrocih in mladostnikih (glejte poglavje 4.4).
If a patient with severe COPD has experienced pneumonia, treatment with Aerivio Spiromax should be re-evaluated. 
Če je bolnik s hudo obliko KOPB zbolel za pljučnico, je treba zdravljenje z zdravilom Aerivio Spiromax ponovno oceniti.
If this happens stop using your Aerivio Spiromax inhaler. 
Če se to zgodi, prenehajte uporabljati inhalator z zdravilom Aerivio Spiromax.
Just take your next dose at the usual time. 
Naslednji odmerek uporabite ob
What Aerivio Spiromax is and what it is used for 
Kaj je zdravilo Aerivio Spiromax in za kaj ga uporabljamo
What Aerivio Spiromax looks like and contents of the pack Aerivio Spiromax is an inhalation powder. 
Izgled zdravila Aerivio Spiromax in vsebina pakiranja Zdravilo Aerivio Spiromax je prašek za inhaliranje.
Subjects were randomised 1:1 to salmeterol/FP 50/250 (total ITT n=776) or salmeterol (total ITT n=778). 
Osebe so bile randomizirane v razmerju 1 : 1 v skupino s salmeterolom/FP 50/250 mikrogramov (celotna skupina z namenom zdravljenja (ITT, intent-to-treat) n = 776) ali s salmeterolom (celotna skupina ITT n = 778).
Patients should commence treatment with a fixeddose combination containing a lower dose of the corticosteroid component and will then be titrated up in respect of the corticosteroid dose until control of asthma is achieved. 
Bolniki naj zdravljenje začnejo s fiksno kombinacijo odmerka, ki vsebuje manjši odmerek sestavine kortikosteroida, nato pa se odmerek kortikosteroida povečuje, dokler ni dosežen nadzor nad astmo.
As such, the patients should be advised to read the patient information leaflet carefully and follow the instructions for use as detailed in the leaflet. 
Bolniku je zato treba svetovati, da natančno prebere navodilo za uporabo zdravila in upošteva navedena navodila za uporabo inhalatorja.
It is recommended that the height of children receiving prolonged treatment with inhaled corticosteroids is regularly monitored. 
Višino otrok, ki se dlje časa zdravijo z inhalacijskimi kortikosteroidi, je priporočljivo redno spremljati.
The remainder of the inhaled dose of fluticasone propionate may be swallowed but contributes minimally to systemic exposure due to the low aqueous solubility and presystemic metabolism, resulting in oral availability of less than 1%. 
Preostanek vdihanega odmerka bolnik sicer lahko pogoltne, vendar to zaradi majhne vodotopnosti in zaradi predsistemske presnove le minimalno pripomore k sistemski izpostavljenosti, tako da je peroralna uporabnost manj kot 1 %.
Remove the Spiromax device from the mouth and hold the breath for 10 seconds or as long as comfortable for the patients. 
Pripomoček Spiromax odstranite iz ust in zadržite dih 10 sekund ali
Aerivio Spiromax is not intended as the treatment of asthma when a fixed-dose combination of salmeterol and fluticasone propionate is required for the first time. 
Zdravilo Aerivio Spiromax ni primerno za zdravljenje astme, če je fiksna kombinacija odmerka salmeterola in flutikazonpropionata potrebna prvič.
Once control of asthma is achieved patients should be reviewed regularly and the dose of inhaled corticosteroid titrated downwards as appropriate to maintain disease control. 
Ko je dosežen nadzor nad astmo, je treba bolnike redno pregledovati in zmanjševati odmerek inhalacijskega kortikosteroida, kot je ustrezno za ohranjanje nadzora nad boleznijo.
In animal reproduction studies, glucocorticosteroids have been shown to induce malformations (cleft palate, skeletal malformations). 
S študijami toksičnega vpliva na sposobnost razmnoževanja pri živalih je bilo dokazano, da lahko kortikosteroidi povzročijo pojav malformacij (razcepljeno nebo, malformacije skeleta).
The excipient lactose may contain small amounts of milk proteins which may cause allergic reactions in those with severe hypersensitivity or allergy 
Pomožna snov laktoza lahko vsebuje majhne količine mlečnih beljakovin, ki lahko povzročijo alergijske reakcije pri bolnikih s hudo preobčutljivostjo ali alergijo na mlečne beljakovine.
Aerivio Spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate: 
Zdravilo Aerivio Spiromax je indicirano za redno zdravljenje bolnikov s hudo astmo, pri katerih je primerna uporaba kombiniranega zdravila (inhalacijskega kortikosteroida in dolgodelujočega agonista
There are no data available from clinical trials on overdose with Aerivio Spiromax, however data on overdose with both active substances are given below: 
Podatkov o prevelikem odmerjanju zdravila Aerivio Spiromax iz kliničnih preskušanj ni; podatki o prevelikem odmerjanju z obema zdravilnima učinkovinama so navedeni spodaj:
Studies have shown that salmeterol and fluticasone propionate and their metabolites, are excreted into the 
Študije so pokazale, da se salmeterol in flutikazonpropionat ter njuni presnovki izločajo v mleko pri
In a population pharmacokinetic analysis from 9 controlled clinical trials of 350 patients with asthma aged 4 to 77 years (174 patients 4 to 11 years of age) higher fluticasone propionate systemic exposure following treatment with salmeterol/fluticasone propionate inhalation powder 50/100 compared with fluticasone propionate inhalation powder 100 was seen. 
V analizi populacijske farmakokinetike iz 9 kontroliranih kliničnih preskušanj pri 350 bolnikih z astmo, starih od 4 do 77 let (174 bolnikov od 4 do 11 let), so opazili večjo sistemsko izpostavljenost flutikazonpropionatu po zdravljenju s salmeterolom/flutikazonpropionatom 50/100 mikrogramov, v primerjavi s flutikazonpropionatom 100 mikrogramov.
Aerivio Spiromax should be administered with caution in patients with active or quiescent pulmonary tuberculosis and fungal, viral or other infections of the airway. 
Zdravilo Aerivio Spiromax je treba uporabljati previdno pri bolnikih z aktivno ali mirujočo pljučno tuberkulozo ter pri glivičnih, virusnih ali drugih okužbah dihal.
Do not breathe through your inhaler. 
Ne dihajte skozi inhalator.
Percentage of Patients Attaining *Well Controlled (WC) and **Totally Controlled (TC) Asthma over 
Odstotek bolnikov, ki so dosegli *dobro nadzorovanost (DN) in **popolno nadzorovanost (PN) astme v 12 mesecih Salmeterol/FP
Physicians should remain vigilant for the possible development of pneumonia and other lower respiratory tract infections in patients with COPD as the clinical features of such infections and exacerbation frequently overlap. 
Zdravniki morajo budno spremljati možnost razvoja pljučnice ali okužbe spodnjih dihal pri bolnikih s KOPB, saj se klinične lastnosti takih okužb in poslabšanje KOPB pogosto prekrivajo.
Potentially serious hypokalaemia may result from β2 agonist therapy. 
Zdravljenje z agonisti β2 lahko povzroči resno hipokaliemijo.
D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE 
D. POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO
This possibility of residual impairment should always be borne in mind in emergency and elective situations likely to produce stress, and appropriate corticosteroid treatment must be considered. 
V nujnih primerih in v elektivnih okoliščinah, v katerih je verjeten stres, je vedno treba upoštevati možnost rezidualne okvare in poskrbeti za ustrezno zdravljenje s kortikosteroidi.
If you open and close the mouthpiece without taking an inhalation the dose indicator will still register it as a count. 
Če ustnik odprete in zaprete brez inhaliranja, to kazalnik odmerka registrira in odšteje.
In an interaction study in healthy subjects with intranasal fluticasone propionate, ritonavir (a highly potent cytochrome P450 3A4 inhibitor) 100 mg twice daily increased the fluticasone propionate plasma concentrations several hundred fold, resulting in markedly reduced serum cortisol concentrations. 
V študiji medsebojnega delovanja pri zdravih preiskovancih, ki so uporabljali flutikazonpropionat intranazalno, je ritonavir (zelo močan zaviralec citokroma P450 3A4) v odmerku 100 mg dvakrat na dan večstokrat zvišal koncentracijo flutikazonpropionata v plazmi, kar je povzročilo izrazito znižanje kortizola v serumu.
Peak Inspiratory Flow Rate through the Spiromax Device A randomised, open-label cross-over study was performed in children and adolescents with asthma (aged 417 years), adults with asthma (aged 18-45 years), adults with chronic obstructive pulmonary disease (COPD) (aged older than 55 years) and healthy volunteers (aged 18-45 years) to evaluate the peak inspiratory flow rate (PIFR) and other related inhalation parameters following inhalation from a Spiromax device (containing placebo) compared with inhalation from an already marketed multi-dose dry powder inhaler device (containing placebo). 
Največja inspiratorna hitrost pretoka skozi pripomoček Spiromax Pri otrocih in mladostnikih z astmo (starih od 4 do 17 let), odraslih z astmo (starih od 18 do 45 let), odraslih s kronično obstruktivno pljučno boleznijo (KOPB) (starejših od 55 let) in zdravih prostovoljcih (starih od 18 do 45 let) so opravili randomizirano, odprto križno študijo za ocenitev največje inspiratorne hitrosti pretoka (PIFR, peak inspiratory flow rate) in drugih povezanih inhalacijskih parametrov po inhaliranju iz pripomočka Spiromax (s placebom) v primerjavi z inhaliranjem iz večodmernega pripomočka za inhaliranje s suhim praškom (s placebom), ki je na trgu.
COPD patients with a baseline (pre-bronchodilator) FEV1 <60% of predicted normal were randomised to double-blind medication. 
Bolniki s KOPB z izhodiščno (pred bronhodilatatorjem) FEV1 < 60 % predvidene normalne vrednosti so bili randomizirani v skupine za dvojno slepo zdravljenje.
• Use within 3 months of removing from the foil wrapping. 
• Uporabite v 3 mesecih od odstranitve ovoja iz folije.
In cases of both acute and chronic fluticasone propionate overdose Aerivio Spiromax therapy should be continued at a suitable dose for symptom control. 
Pri akutnem in kroničnem prevelikem odmerjanju flutikazonpropionata je treba zdravljenje z zdravilom Aerivio Spiromax nadaljevati z ustreznim odmerkom za nadzorovanje simptomov.
Therapy should be down-titrated under physician supervision. 
Zdravljenje je treba zmanjševati pod zdravniškim nadzorom.
Patients should be made aware that Aerivio Spiromax must be used daily for optimum benefit, even when asymptomatic. 
Bolnikom je treba pojasniti, da morajo za najboljši učinek zdravilo Aerivio Spiromax uporabljati vsak dan, tudi kadar nimajo simptomov.
Patients should be advised to have their inhaler to be used for relief in an acute asthma attack available at all times. 
Bolnikom naročite, naj imajo vedno pri sebi svoj inhalator, ki ga uporabljajo za olajšanje akutnega napada astme.
The average improvement over three years for salmeterol/fluticasone propionate compared with placebo was -3.1 units (95% CI: -4.1 to -2.1; p<0.001) and when compared with salmeterol was -2.2 units (p<0.001) and when compared with FP was -1.2 units (p=0.017). 
Povprečno izboljšanje v treh letih za salmeterol/flutikazonpropionat v primerjavi s placebom je bilo -3,1 enote (95-odstotni IZ: -4,1 do -2,1; p < 0,001), v primerjavi s salmeterolom -2,2 enoti (p < 0,001) in v primerjavi s FP -1,2 enoti (p = 0,017).